In: Marriott BP, Birt DF, Stallings VA, Yates AA, eds
Still, when it was noted that the drug helped to manage body weight, it was also studied and approved as a weight-loss treatment
In the 28-week, phase three randomized control trial (RCT) DURATION-8, dual therapy with an SGLT2 inhibitor (dapagliflozin) and a GLP-1RA (once-weekly exenatide) was shown to reduce HbA1c by 0.4% more than either agent alone, in patients with a starting HbA1c of between 8-12% 50 , illustrating that the glycemic response to dual therapy is less than additive 50
Ive seen lifelong weight loss strugglers people who never felt they could push away a plate or be in control making changes theyve always wanted to
C., Cooper-Cox, K
Starting at just $179/month & includes visit and meds Our Semaglutide contains no fillers